Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

How was the $10 billion asset value estimated and what assumptions underpin that valuation? Which specific assets or projects contribute most to the $10 billion figure? What is the timeline for realizing the stated asset value – short‑term, mid‑term, or long‑term? How does this valuation compare to the current market capitalization of TVGN? What impact could this announcement have on TVGN's stock price and trading volume in the next few days? Are there any pending regulatory approvals or milestones required to unlock the estimated asset value? How will the announced valuation affect the company’s balance sheet, debt covenants, and financing capacity? What is the expected impact on earnings per share and cash flow forecasts? Will the company issue new shares, debt, or other securities to monetize the assets? How does this valuation compare to peers in the biotech/healthcare sector? What are the risks if the asset valuation does not materialize as expected? What are the potential dilution effects for existing shareholders? How will this news affect analyst coverage, target price revisions, and consensus estimates? What is the market’s perception of the credibility of this announcement – are there independent verifications? What are the tax implications of the reported asset value for the company and shareholders? How does this announcement align with the company's previous guidance and financial outlook? What are the potential impacts on the company's R&D pipeline and future product launches? What is the expected impact on institutional ownership and investor sentiment? How might this news influence the company’s strategic options such as M&A, joint ventures, or licensing deals?